Jena, Germany
Jena, Germany

Time filter

Source Type

Patent
Alere Technologies GmbH | Date: 2015-02-23

The present invention relates to methods for determining the presence and/or amount of multiple nucleic acids in a sample.


Patent
Alere Technologies GmbH | Date: 2016-12-28

The present invention relates to methods for determining the presence and/or amount of multiple nucleic acids in a sample.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: KBBE-2007-1-1-05 | Award Amount: 8.96M | Year: 2009

With the increasing impact of mankinds activities on the natural environment, disease naturally harboured by wild animals, both within the geographical limits of the EU and elsewhere, are becoming increasingly significant both for public health and health of livestock, in addition to having direct concerns for wild animal species. We are proposing a project which will combine (i) technological development to enable high through-put array-based screening of samples from a wide variety of wild animals with (ii) surveillance of terrestrial, aerial and marine wild animal species within Europe and from countries which act as portals of disease entry into the EU, (iii) epidemiological analysis and risk assessment using data generated during the project and from other sources, and (iv) development and proposal of a model framework for disease surveillance within Europe developed in parallel with the burgeoning systems in North America. The proposal will place the EU at the centre of wildlife disease surveillance and also enable the translation of high throughput array-based technologies into human and veterinary medicine.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2010.2.3.2-1 | Award Amount: 16.70M | Year: 2011

The More Medicines for Tuberculosis (MM4TB) consortium evolved from the highly successful FP6 project, New Medicines for TB (NM4TB), that delivered a candidate drug for clinical development two years ahead of schedule. Building on these firm foundations and exploiting its proprietary pharmacophores, MM4TB will continue to develop new drugs for TB treatment. An integrated approach will be implemented by a multidisciplinary team that combines some of Europes leading academic TB researchers with two major pharmaceutical companies and four SMEs, all strongly committed to the discovery of anti-infective agents. MM4TB will use a tripartite screening strategy to discover new hits in libraries of natural products and synthetic compounds, while concentrating on both classical and innovative targets that have been pharmacologically validated. Whole cell screens will be conducted against Mycobacterium tuberculosis using in vitro and ex vivo models for active growth, latency and intracellular infection. Hits that are positive in two or more of these models will then be used for target identification using functional genomics technologies including whole genome sequencing and genetic complementation of resistant mutants, yeast three hybrid, click chemistry and proteomics. Targets thus selected will enter assay development, structure determination, fragment-based and rational drug design programs; functionally related targets will be found using metabolic pathway reconstruction. Innovative techniques, based on microfluidics and array platforms, will be used for hit ranking, determining rates of cidality and confirming mechanism of action. Medicinal chemistry will convert leads to molecules with drug-like properties for evaluation of efficacy in different animal models and late preclinical testing.


Rasmussen G.,Örebro University | Monecke S.,Alere Technologies GmbH | Monecke S.,TU Dresden | Ehricht R.,Alere Technologies GmbH | Soderquist B.,Örebro University
PLoS ONE | Year: 2013

Staphylococcus aureus encodes a remarkable number of virulence factors which may contribute to its pathogenicity and ability to cause invasive disease. The main objective of this study was to evaluate the association between S. aureus invasiveness and bacterial genotype, in terms of the presence of virulence genes and affiliation to clonal complexes. Also, the significance of different virulence genes, mainly adhesins, for the development of infective endocarditis was investigated.DNA microarray technology was used to analyze 134 S. aureus isolates, all methicillin-susceptible, derived from three groups of clinically well-characterized patients: nasal carriers (n=46), bacteremia (n=55), and bacteremia with infective endocarditis (n=33).Invasive isolates were dominant in four of the major clonal complexes: 5, 8, 15, and 25. Of the 170 virulence genes examined, those encoding accessory gene regulator group II (agr II), capsule polysaccharide serotype 5 (cap5), and adhesins such as S. aureus surface protein G (sasG) and fibronectin-binding protein B (fnbB) were found to be associated with invasive disease. The same was shown for the leukocidin genes lukD/lukE, as well as the genes encoding serine protease A and B (splA/splB), staphylococcal complement inhibitor (scn) and the staphylococcal exotoxin-like protein (setC or selX). In addition, there was a trend of higher prevalence of certain genes or gene clusters (sasG, agr II, cap5) among isolates causing infective endocarditis compared to other invasive isolates. In most cases, the presence of virulence genes was linked to clonal complex affiliation.In conclusion, certain S. aureus clonal lineages harboring specific sets of virulence genes seem to be more successful in causing invasive disease. © 2013 Rasmussen et al.


Shore A.C.,University College Dublin | Deasy E.C.,University College Dublin | Slickers P.,Alere Technologies GmbH | Brennan G.,St James's Hospital | And 4 more authors.
Antimicrobial Agents and Chemotherapy | Year: 2011

Methicillin resistance in staphylococci is mediated by penicillin binding protein 2a (PBP 2a), encoded by mecA on mobile staphylococcal cassette chromosome mec (SCCmec) elements. In this study, two clonal complex 130 (CC130) methicillin-resistant Staphylococcus aureus (MRSA) isolates from patients in Irish hospitals were identified that were phenotypically PBP 2a positive but lacked mecA by conventional PCR and by DNA microarray screening. The isolates were identified as methicillin-susceptible S. aureus using the GeneXpert real-time PCR assay. Whole-genome sequencing of one isolate (M10/0061) revealed a 30-kb SCCmec element encoding a class E mec complex with highly divergent blaZ-mecA-mecR1-mecI, a type 8 cassette chromosome recombinase (ccr) complex consisting of ccrA1-ccrB3, an arsenic resistance operon, and flanking direct repeats (DRs). The SCCmec element was almost identical to that of SCCmec type XI (SCCmec XI) identified by the Sanger Institute in sequence type 425 bovine MRSA strain LGA251 listed on the website of the International Working Group on the Classification of Staphylococcal Cassette Chromosome Elements. The open reading frames (ORFs) identified within SCCmec XI of M10/0061 exhibited 21 to 93% amino acid identity to ORFs in GenBank. A third DR was identified ca. 3 kb downstream of SCCmec XI, indicating the presence of a possible SCC remnant. SCCmec XI was also identified in the second CC130 MRSA isolate by PCR and sequencing. The CC130 MRSA isolates may be of animal origin as previously reported CC130 S. aureus strains were predominantly from bovine sources. The highly divergent nature of SCCmec XI relative to other SCCmec elements indicates that it may have originated in another taxon. Copyright © 2011, American Society for Microbiology. All Rights Reserved.


Patent
Alere Technologies GmbH | Date: 2013-06-17

The present invention relates to devices and methods for the qualitative and/or quantitative detection of particles. In particular, the invention relates to devices for the detection of particles, comprising a reaction chamber formed within a chamber body between a first surface and a second surface, wherein the second surface is located opposite to the first surface, and one or more displacers, wherein the distance between the first surface and the second surface is variable via the one or more displacers at least in one or more parts of the surface area of the first surface and/or second surface. The invention also relates to corresponding methods for the detection of particles.


A method for the transformation of material (e.g. plastic material) into an optically modulating state via laser radiation is described. The optically modulating state may be a state in which light is emitted at a different wavelength than it is absorbed. The plastic material to may be a thermoplastic or elastomeric material, or an organic polymer selected from the group consisting of polyethylene, polypropylene, polystyrene, polycarbonate and polycycloolefin. The laser radiation may comprise the application of an amount of energy of about 0.1 nJoule/m^(2 )to about 100 Joule/m^(2 )and/or may comprise a radiation of a wavelength of about 355 nm to about 1064 nm. The optically modulating state of the plastic material may absorb light in a wavelength spectrum of about 380 nm to about 540 nm and/or a wavelength spectrum of about 635 nm to about 655 nm. The optically modulating state of the plastic material may emit light in a wavelength spectrum of about 550 nm to about 800 nm. The transformation of the plastic material may comprise the generation of optically modulating elements on the surface of said plastic material, selected from the group comprising geometrical forms, geometrical pattern, spots, dots, lines, circles, squares, characters, symbols, drawings, barcode and datamatrixcode. The material may be used as component for the manufacture of a device, microfluidic device, system, cartridge or instrument. Based on the employment of the material the usability of a device or system and/or of any procedure, function or method carried out with it or in it may be determined and/or controlled.


Described herein is a method and assay of detecting the presence of a polynucleotide in a bodily fluid obtained from a subject treated with an anti-pathogenic agent comprising isolating the polynucleotide from a first and a second sample of a bodily fluid, amplifying the polynucleotide, and determining the polynucleotide, wherein the polynucleotide is a pathogen polynucleotide. Further provided is a method for diagnosing a pathogen infection in a subject, for detecting a pathogen infection in a subject treated with an anti-pathogenic agent, and for detecting the presence and/or genotype of a pathogen in a bodily fluid.


Patent
Alere Technologies GmbH | Date: 2011-10-14

The present invention relates to devices and methods for the qualitative and/or quantitative detection of particles. In particular, the invention relates to devices for the detection of particles, comprising a reaction chamber formed within a chamber body between a first surface and a second surface, wherein the second surface is located opposite to the first surface, and one or more displacers, wherein the distance between the first surface and the second surface is variable via the one or more displacers at least in one or more parts of the surface area of the first surface and/or second surface. The invention also relates to corresponding methods for the detection of particles.

Loading Alere Technologies GmbH collaborators
Loading Alere Technologies GmbH collaborators